Acquired perforating dermatosis associated with risankizumab

Acquired perforating dermatosis associated with risankizumab

Detalhes bibliográficos
Principais autores:	Munira Alhadlg, MD, Ghadah Alhammad, MD, Abdulaziz Madani, MD
Formato:	Artigo
Idioma:	English
Publicado em:	Elsevier 2024-03-01
coleção:	JAAD Case Reports
Assuntos:	acquired perforating dermatosis interleukin-23 inhibitor risankizumab
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2352512624000353

Registros relacionados

Cabozantinib-associated acquired perforating dermatosis
por: Denis Smirnov, MD, PhD, et al.
Publicado em: (2024-10-01)

Acquired perforating dermatosis successfully treated with dupilumab
por: Omar Alwattar‐Ceballos, et al.
Publicado em: (2023-12-01)

Scabies‐induced perforating dermatosis successfully treated with low dose methotrexate
por: Elena Ippoliti, et al.
Publicado em: (2024-03-01)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
por: Lauren M. Fahmy, BS, et al.
Publicado em: (2023-11-01)

Acquired Perforating Dermatosis: Clinical and Histopathological Analysis of 95 Patients From One Center
por: Yusuf Can Edek, et al.
Publicado em: (2024-04-01)

Refractory dissecting cellulitis of the scalp treated with risankizumab: 2 case reports
por: Khalid Nabil Nagshabandi, MBBS, et al.
Publicado em: (2023-12-01)

Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
por: Laurent Peyrin-Biroulet, et al.
Publicado em: (2024-01-01)

Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
por: Joseph F. Merola, et al.
Publicado em: (2024-12-01)

Acquired reactive perforating dermatosis within poikiloderma of Civatte elicited by narrow‐band UVB therapy for psoriasis
por: G. Gaitanis, et al.
Publicado em: (2025-03-01)

Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials
por: Shawn G. Kwatra, et al.
Publicado em: (2024-05-01)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
por: Ahmed Bagit, BSc, et al.
Publicado em: (2023-09-01)

A Case of Acquired Reactive Perforating Dermatosis with Complete Resolution of Eruptions on Upper and Lower Limbs During the Treatment of Diabetes Mellitus and Peripheral Artery Disease
por: Yoshihito Mima, et al.
Publicado em: (2024-12-01)

Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience
por: Gönülal M, et al.
Publicado em: (2023-12-01)

Bullous Pemphigoid with secondary Acquired Reactive Perforating Collagenosis: a challenging clinical case report
por: Valentina Ruffo di Calabria, et al.
Publicado em: (2024-10-01)

Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children
por: Marta Kołt-Kamińska, et al.
Publicado em: (2023-09-01)

Acquired Perforating Dermatosis as a Paraneoplastic Feature: A Case Report, Literature Review, and Novel Association
por: Nashat Imran
Publicado em: (2023-06-01)

Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)
por: Diego Orsini, et al.
Publicado em: (2024-12-01)

Risankizumab for the treatment of pityriasis rubra pilaris postanaplastic large cell lymphoma
por: Georgia Koroneos, BSc, MD, et al.
Publicado em: (2024-06-01)

Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials
por: Kenneth B. Gordon, et al.
Publicado em: (2024-08-01)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
por: Fabrizio Calapai, et al.
Publicado em: (2023-07-01)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
por: Megna M, et al.
Publicado em: (2023-12-01)

Risankizumab: Daily Practice Experience of High Need Patients
por: Alexandra M. G. Brunasso, et al.
Publicado em: (2023-06-01)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
por: Megna M, et al.
Publicado em: (2024-06-01)

IL-23 Inhibitors to treat psoriatic arthritis: A systematic review & meta-analysis of randomized controlled trials
por: Ahmed Safi Vahidy, et al.
Publicado em: (2023-12-01)

Rapidly and successful improvement of nail psoriasis with risankizumab
por: Diego Orsini, et al.
Publicado em: (2023-10-01)

Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Qin-Yi Su, et al.
Publicado em: (2024-02-01)

Dermatosis perforante adquirida e Índice de Calidad de Vida en Dermatología en pacientes en hemodiálisis
por: Sonia Estrella Roldan-Contreras, et al.
Publicado em: (2024-03-01)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
por: Martora F, et al.
Publicado em: (2023-09-01)

Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series
por: Kanako Tsunoda, MD, PhD, et al.
Publicado em: (2024-09-01)

Response to upadacitinib monotherapy in a patient with eczematid-like pigmented purpuric dermatosis
por: Aditi Chokshi, DO, et al.
Publicado em: (2025-02-01)

A potential new treatment with upadacitinib for acquired reactive perforating collagenosis
por: Wei Ding, BS, et al.
Publicado em: (2024-06-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
por: Cathrine Dawn Büttner Elgaard, et al.
Publicado em: (2023-12-01)

Acquired Reactive Perforating Collagenosis
por: Arzu Ataseven, et al.
Publicado em: (2012-04-01)

Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months
por: Diamant Thaçi, et al.
Publicado em: (2025-02-01)

Recalcitrant Reactive Perforating Collagenosis Successfully Treated with Dupilumab: A Case Report
por: Li J, et al.
Publicado em: (2024-06-01)

Recalcitrant pityriasis rubra pilaris in a Middle Eastern patient and arguments for early anti‐IL‐23 targeting
por: Mohammed N. Al‐Abdulla, et al.
Publicado em: (2024-09-01)

Recalcitrant Reactive Perforating Collagenosis Successfully Treated with Dupilumab: A Case Report [Corrigendum]
por: Li J, et al.
Publicado em: (2024-07-01)

Linear IgA bullous dermatosis
por: L. F. Znamenskaya, et al.
Publicado em: (2019-04-01)

Linear IgA bullous dermatosis induced by nemvaleukin alfa, an engineered interleukin 2 molecule, in a patient with treatment-refractory metastatic melanoma
por: Fatima Bawany, MD, et al.
Publicado em: (2023-11-01)

Successful management of a severe case of chronic giant acquired reactive perforating collagenosis with allopurinol
por: Aryan Naik, BS, et al.
Publicado em: (2023-10-01)